English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Vaccibodies are recombinant molecules that can elicit strong CD4+ T lymphocyte and antibody responses and have shown promising results in treatment of B lymphomas and multiple myelomas in mice. The vaccibody is a bivalent homodimer and consists of three functional units; an N-terminal targeting unit, a dimerization unit and a C-terminal antigenic unit. In order to elucidate whether such molecules could be exploited in vaccination against HIV, we inserted gp120 in the antigenic unit. Furthermore, two molecules were tested for their targeting properties: i) the chemokine MIP-1alpha (CCL3) and, ii) V regions that specifically bind MHC class II. Mutated murine MIP-1alpha (mMIP-1alphaC11S) unable to bind its receptors and non-targeted control specific for NIP, were included as negative controls.

P19-39. Vaccibodies: a novel vaccine strategy for HIV that target viral antigens to APC